Graceway Pharmaceuticals
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Graceway Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Graceway Pharmaceuticals: 17 sponsored US clinical trials, none currently recruiting.
Graceway Pharmaceuticals sponsors 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 17 completed. 8 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Keratosis, with 2 trials.
Top-decile sponsor footprint
Graceway Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
17 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
17 total, page 1 of 1
Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis
NCT01055106
Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery
NCT00894647
Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
NCT00735462
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
NCT00674739
Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
NCT00605176
Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)
NCT00603798
A Study to Validate Cosmetic Outcome Scales Used to Rate Uneven Skin Color and Wrinkling
NCT00114673
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
NCT00116649
Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands
NCT00115154
An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
NCT00116662
Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
NCT00116675
1-Year Follow up to the 1473-IMIQ Study
NCT00114023
Study With a Topical Gel to Treat Common Warts in Adults
NCT00117871
Study With a Topical Gel to Treat Common Warts in Adults
NCT00117923
Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
NCT00114920
A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
NCT00129519
Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream
NCT00335179
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 7 |
| Phase 3 | 6 |
| Phase 4 | 2 |
Therapeutic Areas
How the Graceway Pharmaceuticals archive is shaped
17 indexed studies, none listed as recruiting (0% open); 17 completed (100%).
Phase mix: 8 late (III/IV) vs 7 early (I/II) (balanced across stages).
Top condition: Keratosis (2 trials), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Graceway Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 17 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Graceway Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 archived trials
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Graceway Pharmaceuticals page
17 registered trials is a research-attention snapshot, not an endorsement of Graceway Pharmaceuticals or any single study.
- None of Graceway Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Keratosis is the condition Graceway Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Keratosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Graceway Pharmaceuticals pipeline card: 17 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.